XRCC1 polymorphisms and risk of colorectal cancer: a meta-analysis
Previous studies investigating the association between X-ray repair cross-complementation group 1 (XRCC1) polymorphisms and colorectal cancer (CRC) risk has provided inconsistent results. The aim of our study was to clarify the effects of XRCC1variants on CRC risk.
Materials and methods
We conducted searches of the published literature in PubMed, Embase, and CBM databases up to July 6, 2009. Meta-analysis was performed by critically reviewing 14 studies with a total of 2,776 CRC cases and 4,402 controls on Arg399Gln polymorphism, four studies with a total of 931 CRC cases and 1,547 controls on Arg280His polymorphism, and nine studies with a total of 1,709 CRC cases and 3,233 controls on Arg194Trp polymorphism, respectively. Statistical analysis was performed with the software programs Review Manager (version 5.0.10) and STATA (version 9.2).
No significant association between Arg399Gln polymorphism and CRC risk was observed in both total population analyses and subgroup analyses based on ethnicity (ORCo-dominant model = 1.04, 95% CI 0.74–1.45, P OR = 0.82; ORDominant model = 1.02, 95% CI 0.80–1.30, P OR = 0.88; OR Recessive model = 1.04, 95% CI 0.81–1.34, P OR = 0.78). Arg280His polymorphism also had no significant association with CRC risk (ORCo-dominant model = 0.85, 95% CI 0.32–2.31, P OR = 0.76; ORDominant model = 1.11, 95% CI 0.87–1.40, P OR = 0.40; ORRecessive model = 0.85, 95% CI 0.32–2.31, P OR = 0.75). Besides, there was also no evidence of association between Arg194Trp polymorphism and CRC risk (ORCo-dominant model = 1.43, 95% CI 0.83–2.48, P OR = 0.20; ORDominant model = 1.14, 95% CI 0.87–1.51, P OR = 0.34; ORRecessive model = 1.32, 95% CI 0.82–2.13, P OR = 0.25).
No association is found between the polymorphisms in XRCC1 (Arg399Gln, Arg280His, and Arg194Trp) and risk of colorectal cancer.
KeywordsColorectal cancer Gene polymorphism X-ray repair cross-complementation group 1 Single nucleotide polymorphism Meta-analysis
We thank Dr. Zhang, the Department of General Surgery, Changhai Hospital, Shanghai, China for providing serviceable advice on our study.
Conflict of interest
The authors declare that they have no conflict of interest.
- 27.Song HN, Liu XL, E YX et al (2008) The correlative study of the XRCC1 gene haplotype and risk of colorectal cancer in China. J Qiqihar Med Col 29:2957–2960 [Article in Chinese]Google Scholar
- 28.Ren Z, Pan WD, Zhuo CZ et al (2007) Chin J Exp Surg 24:1087–1089 [Aticle in Chinese]Google Scholar
- 30.Martinez-Balibrea E, Manzano JL, Martinez-Cardus A et al (2007) Combined analysis of genetic polymorphisms in thymidylate synthase, uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil plus oxaliplatin or irinotecan. Oncol Rep 17:637–645PubMedGoogle Scholar
- 42.Geng J, Zhang Q, Zhu C, Wang J, Chen L (2009) XRCC1 genetic polymorphism Arg399Gln and prostate cancer risk: a meta-analysis. Urology 72:4648–4653Google Scholar